Delving into the Latest Updates on Carboplatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Carboplatin (JP17/USP/INN), CBDCA, cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)

+ [11]

Target

DNA

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesCongenital Disorders+ [11]

Active Indication

Endometrial CarcinomaBreast CancerEwing Sarcoma+ [68]

Inactive Indication

AdenocarcinomaAdenocarcinoma of EsophagusAdenocarcinoma of prostate+ [85]

Originator Organization

Active Organization

+ [17]

Inactive Organization

Sanofi

Pfizer Inc.

Novartis Pharmaceuticals Corp.

+ [14]

Drug Highest PhaseApproved

First Approval Date

US (03 Mar 1989),

Ovarian Cancer

RegulationOrphan Drug (US), Orphan Drug (EU)

Login to view timeline

Structure/Sequence

Molecular FormulaC6H12N2O4Pt

InChIKeyOLESAACUTLOWQZ-UHFFFAOYSA-L

CAS Registry41575-94-4

9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma [ACC]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.

Start Date18 Dec 2030

Sponsor / Collaborator

Actuate Therapeutics, Inc.Startup

NCT04419181

/ SuspendedPhase 2IIT

A Feasibility Study of De-escalation of Chemotherapy in Patients with Early-Stage HER2 Positive Breast Cancer

The main purpose of this research study is to find out if de-escalation of chemotherapy before surgery followed by a selective escalation of adjuvant targeted therapies are efficacious and tolerable in early-stage HER2 positive breast cancer.

Start Date11 Aug 2025

Sponsor / Collaborator

University of Rochester

NCT06688656

/ Not yet recruitingPhase 2IIT

A Phase II Single-Center Exploratory Study on the Efficacy and Safety of Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant Stage II-IIIB Non-Squamous Non-Small Cell Lung Cancer Patients

This study is a prospective, single-arm, single-center Phase II trial, aiming to investigate efficacy and safety of neoadjuvant chemotherapy sequentially combined with sintilimab in resectable EGFR-mutant stage II-IIIB non-squamous NSCLC patients

Start Date31 Mar 2025

Sponsor / Collaborator

Shanghai Chest Hospital

100 Clinical Results associated with Carboplatin

Login to view more data

100 Translational Medicine associated with Carboplatin

Login to view more data

100 Patents (Medical) associated with Carboplatin

Login to view more data

18,728

Literatures (Medical) associated with Carboplatin

01 Dec 2025·CHILDS NERVOUS SYSTEM

Holocord intramedullary pilocytic astrocytoma mimicking holocord spinal abscess: a case report and literature review

Review

Author: Erguven, Merve ; Sabanci, Pulat Akin ; Dolen, Duygu ; Gulsever, Cafer Ikbal ; Unverengil, Gokcen

PURPOSE:

This report aims to present a case of a child with holocord pilocytic astrocytoma and review the existing literature to provide insights into current management strategies.

CASE PRESENTATION:

An 11-month-old patient presented with progressive quadriplegia and was initially diagnosed with a spinal abscess. MRI revealed a heterogeneously enhancing cystic intramedullary lesion extending from the cervicomedullary region to the conus medullaris. The patient underwent an emergent T10-L1 total laminectomy and midline myelotomy for presumed abscess drainage. Intraoperative findings, however, were inconsistent with an abscess, suggesting a neoplastic process. Postoperative MRI indicated persistent spinal cord compression and histopathological examination showed no leukocytes or microorganisms. A second surgery the following day extended the laminectomy to T3, achieving gross total resection. Pathology confirmed a grade I pilocytic astrocytoma. Given the patient's age, chemotherapy with vincristine and carboplatin was initiated, as radiotherapy was unsuitable. Early physical therapy was commenced, resulting in significant neurological improvement to 4/5 muscle strength in all extremities according to the Medical Research Council (MRC) scale in the first year. Chemotherapy was discontinued due to systemic complications. At the 1-year follow-up, MRI demonstrated no tumor recurrence.

CONCLUSION:

The management of holocord pilocytic astrocytomas presents significant challenges, particularly in pediatric patients. While surgical resection remains the cornerstone of treatment, the role of chemotherapy requires further investigation. This case underscores the necessity of a multidisciplinary approach and highlights the potential for favorable outcomes with appropriate intervention.

01 Aug 2025·Neural Regeneration Research

Carboplatin restores neuronal toxicity in FUS-linked amyotrophic lateral sclerosis

Article

Author: Kim, Kiyoung

Amyotrophic lateral sclerosis (ALS), also known as Lou Geh rig′s disease, is a progressive neurodegenerative disorder that affects motor neurons in the brain and spinal cord.This leads to muscle weakness, paralysis, and ultimately, respiratory failure (Cha and Kim, 2022).There is currently no cure for ALS.Riluzole, a primary treatment for ALS, has been shown to extend survival by an average of three months.Another drug, Edaravone, has been approved for ALS treatment in some countries; however, its efficacy remains controversial (Cha and Kim, 2022).These drugs target various mechanisms that contribute to neuronal degeneration in ALS, including glutamate excitotoxicity and oxidative stress.Although several studies have attempted to elucidate the underlying mechanisms, there remains an unmet need for more effective therapies to halt or reverse disease progression.Therefore, novel therapeutic strategies are urgently needed.

01 Mar 2025·INTERNATIONAL JOURNAL OF CANCER

Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/III IMpower 133 trial

Article

Author: Pinato, David J. ; Cortellini, Alessio ; Shimokawa, Mototsugu ; Takamori, Shinkichi ; Takada, Kazuki

Abstract:

The potential impact of concomitant medications such as systemic antibiotics, proton pump inhibitors (PPIs), and probiotics in patients with extensive‐stage small cell lung cancer (ES‐SCLC) receiving first‐line chemo‐immunotherapy combinations remains unclear. We ran a post hoc analysis of the IMpower133 phase I/III trial, which randomized patients with ES‐SCLC to receive carboplatin/etoposide with either atezolizumab or placebo for 4 cycles, followed by maintenance therapy. We included any systemic antibiotic/probiotic exposure within 42 days prior to treatment initiation and any PPIs treatment within 30 days prior to treatment initiation. We explored the potential prognostic impact of antibiotics, PPIs and probiotics across the atezolizumab/chemotherapy and placebo/chemotherapy arms including the multivariable interaction term between the treatment modality and antibiotics/PPIs/probiotics. The analysis included 198 patients in the atezolizumab/chemotherapy arm and 195 in the placebo/chemotherapy arm. Baseline clinic‐pathologic features were well balanced between the two cohorts, with 17 (8.6%) and 14 (7.2%) patients on antibiotics, 43 (21.7%) and 55 (28.2%) on PPIs, and 3 (1.5%) and 5 (2.6%) on probiotics among the atezolizumab/chemotherapy and placebo/chemotherapy cohorts, respectively. Exposure to antibiotics, PPIs, or probiotics was not associated with overall survival or progression free survival in either cohort. Furthermore, interaction terms between these medications and treatment modalities were not statistically significant. Baseline use of antibiotics, PPIs or probiotics did not influence clinical outcomes in patients with ES‐SCLC treated with first‐line atezolizumab/placebo plus chemotherapy, suggesting that they may not have a notable impact on clinical outcomes and could be considered for use in this patient population when necessary.

809

News (Medical) associated with Carboplatin

22 Jan 2025

·pmlive.com

AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi (durvalumab) in NHS patients across England and Wales. Tagrisso has been recommended for use as an adjuvant treatment following complete resection in adults with stage 1B to 3A non-small cell lung cancer (NSCLC) whose tumours express epidermal growth factor (EGFR) exon 19 deletions or exon 21 substitution mutations. Meanwhile, Imfinzi (durvalumab) has been recommended for use in combination with etoposide plus either carboplatin or cisplatin to treat adults with untreated extensive-stage small cell lung cancer (SCLC). Approximately 49,200 people are diagnosed with lung cancer in the UK every year. NSCLC is the most common form of the disease, accounting for around 85% of cases, while SCLC represents approximately 15% of all diagnoses. NICE’s decision on Tagrisso was based on positive results from the late-stage ADAURA trial, in which treatment with the drug after surgery reduced the relative risk of disease recurrence or death by 83% compared to placebo in patients with stage 2 to 3A EGFR-mutated NSCLC. Survival without disease recurrence at two years was 90% for the Tagrisso cohort and 44% for placebo and, among patients with stage 1B to 3A disease, 89% of those being treated with AZ’s drug were alive and disease-free at 24 months compared to 52% in the placebo group. Results from the phase 3 CASPIAN trial supported the health technology assessment agency’s recommendation of Imfinzi. A two-year follow-up analysis of the study showed that first-line treatment with Imfinzi plus platinum chemotherapy demonstrated significant and clinically meaningful improvements in overall survival in patients with extensive-stage SCLC versus chemotherapy alone, and updated results from the trial showed that the Imfinzi combination reduced the risk of death by 29% compared with chemotherapy alone at three years. Tom Keith-Roach, president, AZ UK, said: “This is fantastic news for lung cancer patients. We are proud that these decisions by NICE mean we’ve had 28 positive recommendations by NICE and the Scottish Medicines Consortium since 2021 across multiple cancer types and stages.” The latest recommendations come less than two weeks after the company’s Lynparza (olaparib) was recommended by NICE to treat adults with HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after chemotherapy.

Clinical ResultPhase 3Drug ApprovalADC

21 Jan 2025

·www.pharmaceutical-technology.com

EC approves GSK’s Jemperli-chemo combo for endometrial cancer

Endometrial cancer originates in the endometrium, which is the inner lining of the uterus. Credit: megaflopp/Shutterstock. The European Commission (EC) has approved GSK’s Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial cancer in adults. The decision extends the use of the combination in the European Union (EU) for individuals with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumours. Such tumours account for 75% of individuals with endometrial cancer, and present limited treatment alternatives. The expanded approval is based on the outcomes from Part I of the RUBY Phase III trial – the only study in this setting to demonstrate statistically significant overall survival (OS) benefit across the complete subject population with this cancer type. A 31% decrease in the mortality risk is observed in the trial versus chemotherapy alone. GSK oncology, research and development global head and senior vice-president Hesham Abdullah stated: “For the first time, all patients with primary advanced or recurrent endometrial cancer in the EU have an approved immuno-oncology-based treatment that has shown a statistically significant and clinically meaningful overall survival benefit.” The dual-primary endpoints in Part I were investigator-assessed progression-free survival based on the Response Evaluation Criteria in Solid Tumours v1.1 and OS. At the two-and-a-half-year mark, the probability of survival was 61% for subjects who received the combination, as opposed to 49% for those receiving chemotherapy alone. A median OS improvement of 16.4 months was observed in the combination group compared to the chemotherapy group alone. The tolerability and safety profile for Jemperli combined with carboplatin-paclitaxel was consistent with the known safety profiles of the individual agents. Endometrial cancer originates in the endometrium, which is the inner lining of the uterus. In early January 2025, the company received the US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted antibody-drug conjugate, GSK’227, for treating adults with relapsed or refractory osteosarcoma after a minimum of two lines of previous therapy.

Drug ApprovalPhase 3Breakthrough TherapyClinical ResultAccelerated Approval

20 Jan 2025

·pipelinereview.com

European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer

LONDON, UK I January 20, 2025 I GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This approval broadens the previous indication for Jemperli plus chemotherapy in the European Union (EU) to include patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumours, which represent approximately 75% of patients diagnosed with endometrial cancer and who have limited treatment options. Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said : “For the first time, all patients with primary advanced or recurrent endometrial cancer in the EU have an approved immuno-oncology-based treatment that has shown a statistically significant and clinically meaningful overall survival benefit. We’re proud Jemperli continues to redefine the treatment landscape for patients.” Dr Mansoor Raza Mirza, Chief Oncologist, Copenhagen University Hospital, Denmark, and RUBY principal investigator said : “Clinicians have been waiting for years for an immuno-oncology-based option that can meaningfully improve overall survival outcomes for patients with MMRp/MSS primary advanced or recurrent endometrial cancer. The expanded approval represents a significant advance that delivers on this hope, now for patients with both dMMR/MSI-H and MMRp/MSS tumours.” The European Commission’s approval to expand the use of Jemperli plus chemotherapy is based on results from Part 1 of the RUBY phase III trial. RUBY Part 1 is the only clinical trial in this setting to show a clinically meaningful and statistically significant overall survival (OS) benefit in the full population of patients with primary advanced or recurrent endometrial cancer, demonstrating a 31% reduction in risk of death (HR: 0.69; 95% CI: 0.54–0.89) compared to chemotherapy alone. At the 2.5-year landmark, the chance of being alive was 61% (95% CI: 54-67) for patients in the Jemperli plus chemotherapy group (245 patients) compared to 49% (95% CI: 43-55) in the chemotherapy group (249 patients). In addition, a 16.4-month improvement in median OS was observed with Jemperli plus chemotherapy versus chemotherapy alone (44.6 months [95% CI: 32.6–NR] vs. 28.2 months [95% CI: 22.1–35.6], respectively). The median duration of follow-up was more than three years. 1 The safety and tolerability analysis from RUBY Part 1 showed a safety profile for Jemperli plus carboplatin-paclitaxel that was generally consistent with the known safety profiles of the individual agents. The most common treatment-emergent adverse reactions (≥ 10%) in patients receiving Jemperli plus chemotherapy were rash, rash maculopapular, hypothyroidism, pyrexia, alanine aminotransferase increased, aspartate aminotransferase increased and dry skin. OS data were presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer on 16 March 2024, and were published in Annals of Oncology on 9 June 2024. The label for Jemperli plus chemotherapy in the US was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. About endometrial cancer Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. Endometrial cancer is the most common gynaecologic cancer in developed countries, 2 with an estimated 1.6 million people living with active disease at any stage and 417,000 new cases reported each year worldwide. 3 Incidence rates are expected to rise by approximately 40% between 2020 and 2040. 4 In Europe, approximately 121,000 people are estimated to be diagnosed with primary advanced or recurrent endometrial cancer each year. 5 Approximately 15-20% of patients with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis. 6 Among patients with primary advanced or recurrent endometrial cancer, approximately 75% have MMRp/MSS tumours. 7 About RUBY RUBY is a two-part global, randomised, double-blind, multicentre phase III trial of 785 patients with primary advanced or recurrent endometrial cancer. Part 1 is evaluating dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus carboplatin-paclitaxel plus placebo followed by placebo. Part 2 is evaluating dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo. In Part 1, the dual-primary endpoints are investigator-assessed progression-free survival (PFS) based on the Response Evaluation Criteria in Solid Tumours v1.1 and OS. The statistical analysis plan included pre-specified analyses of PFS in the mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) and overall populations and OS in the overall population. Pre-specified exploratory analyses of PFS and OS in the MMRp/MSS population and OS in the dMMR/MSI-H populations were also performed. RUBY Part 1 included a broad population, including histologies often excluded from clinical trials and had approximately 10% of patients with carcinosarcoma and 20% with serous carcinoma. In Part 2, the primary endpoint is investigator-assessed PFS in the overall population, followed by PFS in the MMRp/MSS population, and OS in the overall population is a key secondary endpoint. Additional secondary endpoints in Part 1 and Part 2 include PFS per blinded independent central review, PFS2, overall response rate, duration of response, disease control rate, patient-reported outcomes, and safety and tolerability. RUBY is part of an international collaboration between the European Network of Gynaecological Oncological Trial groups (ENGOT), a research network of the European Society of Gynaecological Oncology (ESGO) that consists of 22 trial groups from 31 European countries that perform cooperative clinical trials, and the GOG Foundation, a non-profit organisation dedicated to transforming the standard of care in gynaecologic oncology. About Jemperli (dostarlimab) Jemperli , a programmed death receptor-1 (PD-1)-blocking antibody, is the backbone of GSK’s ongoing immuno-oncology-based research and development programme. A robust clinical trial programme includes studies of Jemperli alone and in combination with other therapies in gynaecologic, colorectal and lung cancers, as well as where there are opportunities for transformational outcomes. In the US, Jemperli is indicated in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This includes patients with MMRp/MSS and dMMR/MSI-H tumours. Jemperli is also approved as a single agent for adult patients with dMMR recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. Additionally, Jemperli is indicated in the US for patients with dMMR recurrent or advanced solid tumours, as determined by a US FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. The latter indication is approved in the US under accelerated approval based on tumour response rate and durability of response. Continued approval for this indication in solid tumours may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Jemperli was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., under a collaboration and exclusive license agreement signed in March 2014. Under this agreement, GSK is responsible for the ongoing research, development, commercialisation, and manufacturing of Jemperli and cobolimab (GSK4069889), a TIM-3 antagonist. Important Information for Jemperli in the EU Indication Jemperli is indicated: Refer to the Jemperli EMA Reference Information for a full list of adverse events and the complete important safety information in the EU. GSK in oncology Oncology is an emerging therapeutic area for GSK where we are committed to maximising patient survival with a current focus on haematologic malignancies, gynaecologic cancers, and other solid tumours through breakthroughs in immuno-oncology and tumour-cell targeting therapies. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. References SOURCE: GlaxoSmithKline

Clinical ResultDrug ApprovalPhase 3License out/inASCO

100 Deals associated with Carboplatin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01363	Carboplatin	L01XA02	DB00958

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Endometrial Carcinoma	JP	Clinigen KK	24 Jun 2024
Breast Cancer	JP	Clinigen KK	25 Nov 2011
Breast Cancer	JP	Bristol-Myers Squibb KK	25 Nov 2011
Ewing Sarcoma	JP	Bristol-Myers Squibb KK	15 Sep 2005
Ewing Sarcoma	JP	Clinigen KK	15 Sep 2005
Hepatoblastoma	JP	Bristol-Myers Squibb KK	15 Sep 2005
Hepatoblastoma	JP	Clinigen KK	15 Sep 2005
Neuroblastoma	JP	Clinigen KK	15 Sep 2005
Neuroblastoma	JP	Bristol-Myers Squibb KK	15 Sep 2005
Retinoblastoma	JP	Clinigen KK	15 Sep 2005
Retinoblastoma	JP	Bristol-Myers Squibb KK	15 Sep 2005
Wilms Tumor	JP	Clinigen KK	15 Sep 2005
Wilms Tumor	JP	Bristol-Myers Squibb KK	15 Sep 2005
Non-Small Cell Lung Cancer	JP	Clinigen KK	27 Jul 2000
Non-Small Cell Lung Cancer	JP	Bristol-Myers Squibb KK	27 Jul 2000
Squamous Cell Carcinoma of Head and Neck	CN	Bristol-Myers Squibb SRL	28 Jul 1997
Head and Neck Neoplasms	JP	Clinigen KK	30 Mar 1990
Head and Neck Neoplasms	JP	Bristol-Myers Squibb KK	30 Mar 1990
Lymphoma	JP	Clinigen KK	30 Mar 1990
Lymphoma	JP	Bristol-Myers Squibb KK	30 Mar 1990

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma Multiforme	Phase 3	US	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	BE	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	FR	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	DE	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	IT	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	NL	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	ES	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	CH	CarThera SAS	29 Jan 2024
Recurrent Glioblastoma	Phase 3	US	CarThera SAS	29 Jan 2024
Recurrent Glioblastoma	Phase 3	BE	CarThera SAS	29 Jan 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03980925 (GETNE T1913, CTgov)	Phase 2	Neuroendocrine neoplasm of gastrointestinal tract \| Gastro-Enteropancreatic Neuroendocrine Tumor	37	Nivolumab+Etoposide+Carboplatin	gdrcfrkzuc(pecsmgwrlx) = cdbsihzkfi pecdokqyfq (dfgpqolrhg, gimtutioqj - pexwnvobvx) View more	-	13 Jan 2025
NCT04923776 (CTgov)	Phase 2	Extensive stage Small Cell Lung Cancer	2	Stereotactic Body Radiation Therapy (SBRT)+Etoposide+Carboplatin+Atezolizumab	dbchsktdfo(nteisarthd) = myxvxvbzyi kmxtflqhqc (ugartjxngv, zqfsjdvwog - quolmzpacz) View more	-	30 Dec 2024
NCT03717415 (CTgov)	Phase 1/2	Locally Advanced Malignant Solid Neoplasm \| Metastatic Solid Tumor	70	Carboplatin+Rebastinib (Part 1 Cohort 1 Escalation Rebastinib 50 mg + Carboplatin AUC5)	wcvurrpxxz(soukirzrgp) = odlcorizgs ebgdiuhwsm (uddrusdmgq, clhvmmgjrt - jtdjnueemp) View more	-	27 Dec 2024
				Carboplatin+Rebastinib (Part 1 Cohort 2 Escalation Rebastinib 100 mg + Carboplatin AUC5)	wcvurrpxxz(soukirzrgp) = ekhyvxtnux ebgdiuhwsm (uddrusdmgq, cktandipgn - hhxzskrqyx) View more
NCT05786430 (LUCAS, ESMO_ASIA2024) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	54	Lazertinib + Pemetrexed + Carboplatin	vbhqjjhxtr(lzinudbyrp) = twehlwhzyk uaxievigki (qytoakfbnw, 5.16 - 9.56) View more	Positive	07 Dec 2024
ESMO_ASIA2024 Manual	Not Applicable	Head and Neck Neoplasms	104	Docetaxel plus Cisplatin	hkfggmjrza(dfclbbmcry) = zzszurorij zyhkgosxjh (emvgonaxaw ) View more	Similar	07 Dec 2024
				Paclitaxel plus Carboplatin	hkfggmjrza(dfclbbmcry) = meqodueafs zyhkgosxjh (emvgonaxaw ) View more
NCT04951115 (CTgov)	Phase 2	Small Cell Lung Cancer	6	Stereotactic Body Radiotherapy+Etoposide+Carboplatin+Cisplatin+Durvalumab	wihlworwvm(nhmnofscke) = oeksodgsrb jxsferkgfe (zwnkkxqnur, iosrazstwn - qxfiincule) View more	-	26 Nov 2024
NCT03393884 (OVATION-2, SITC2024) Manual	Phase 1/2	Ovarian Epithelial Carcinoma First line	117	IMNN-001 + NACT	tqapowohfb(nonrfnlrtc) = prgcymtpqu txatbszasb (feuquocypy ) View more	Positive	08 Nov 2024
				NACT	tqapowohfb(nonrfnlrtc) = binpeircaa txatbszasb (feuquocypy ) View more
NCT00980954 (CTgov)	Phase 3	Uterine Cervical Cancer	236	intensity-modulated radiation therapy+cisplatin (Arm I: Cisplatin/Radiation Therapy)	appoevygkf(qcslasaemj) = iljmqvvmsm knbmhzlyga (vqcchagefe, jwssxsqwxy - bgeoxkepsw) View more	-	06 Nov 2024
				intensity-modulated radiation therapy+carboplatin+paclitaxel+cisplatin (Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel)	appoevygkf(qcslasaemj) = ipjpukskhd knbmhzlyga (vqcchagefe, wkjfgypzpq - abnshprrqb) View more
NCT02713386 (NRG-GY007 \| NRG Oncology Group Study, CTgov)	Phase 1/2	Primary peritoneal carcinoma \| Primary Peritoneal High-Grade Serous Adenocarcinoma \| Fallopian Tube Clear Cell Adenocarcinoma ... View more	147	Therapeutic Conventional Surgery+Carboplatin+Paclitaxel (Arm I (Paclitaxel and Carboplatin))	vifqhxicyv(qbtrzovypx) = wyuwqzxrfx slxoywxrtg (ndpxuhlpou, cxzvaqxtim - mjxhusnbln) View more	-	24 Oct 2024
				Therapeutic Conventional Surgery+Carboplatin+Paclitaxel+Ruxolitinib Phosphate (Arm II (Ruxolitinib, Paclitaxel, and Carboplatin))	vifqhxicyv(qbtrzovypx) = xbrxjmkfzr slxoywxrtg (ndpxuhlpou, hgpmqybxbb - tzrpqyosbr) View more
NCT04964960 (CTgov)	Phase 2	Metabolic Syndrome \| Non-Small Cell Lung Cancer \| Brain metastases	3	nab paclitaxel+Carboplatin+Paclitaxel+Pembrolizumab+Pemetrexed	jfhkrhnduj(plkiavcqha) = vlrowanhtx ihstcqfred (yremqbtdqu, hzlzvalcfg - zyfrddowri) View more	-	21 Oct 2024